Rubius marks milestone in PhI/II as CFO departs; Owkin closes $70M Series A; The Carlyle Group bets on Indian CDMO
→ Some of the folks at Rubius Therapeutics weren’t too keen about our lede on the Takeda gene therapy story, which referenced their R …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
